Advertisement

Search Results

Advertisement



Your search for Staff,Staff matches 6765 pages

Showing 801 - 850


kidney cancer

Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus

Thomas Powles, MD, of Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, and Queen Mary University of London, discusses outcomes reported by patients with previously treated renal cell carcinoma (RCC), taking part in the phase III LITESPARK-005 study. Belzutifan was...

bladder cancer

Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab

Amanda Nizam, MD, of the Cleveland Clinic, discusses results from the UNITE study, which shows patients with advanced urothelial cancer who were treated with enfortumab vedotin-ejfv (EV) after switch maintenance avelumab had outcomes consistent with data with EV in platinum- and immune checkpoint...

prostate cancer

Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib

Maha H.A. Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, discusses phase II findings from the BRCAAway trial. This study showed that in patients with metastatic castration-resistant prostate cancer with BRCA1/2 or ATM alterations, abiraterone and...

global cancer care
issues in oncology

UICC Offers Recommendations in Preparation for World Cancer Day 2024

The Union for International Cancer Control (UICC) has provided a new set of recommendations to eliminate inequities in cancer care in light of World Cancer Day on February 4, according to the new World Cancer Day 2024 Equity Report. Background Since its establishment in 2000, World Cancer Day has...

bladder cancer
immunotherapy

Use of Adjuvant Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma: CheckMate 274

Subsequent systemic therapy with the immune checkpoint inhibitor nivolumab may offer overall survival benefit in patients with muscle-invasive urothelial carcinoma who underwent surgery to remove their tumors, according to recent findings presented by Geynisman et al at the 2024 ASCO Genitourinary...

kidney cancer
immunotherapy
issues in oncology

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

Immune checkpoint inhibitor–based therapy may be an equally effective front-line treatment in both Black and White patients with metastatic renal cell carcinoma, according to recent findings presented by Kaur et al at the 2024 ASCO Genitourinary Cancers Symposium (Abstract 369). Background Race may ...

prostate cancer

Neeraj Agarwal, MD, on Prostate Cancer: Phase III Trial Update on Cabozantinib, Atezolizumab, and Hormonal Therapy

Neeraj Agarwal, MD, of Huntsman Cancer Institute at the University of Utah, discusses results of the CONTACT-2 trial, which showed cabozantinib plus atezolizumab improved radiographic progression–free survival of patients with metastatic castration-resistant prostate cancer vs a second novel...

gastroesophageal cancer
gastrointestinal cancer

Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy

Ian Chau, MD, of The Royal Marsden Hospital, discusses reportedly the first study to evaluate the real-world effectiveness of nivolumab as a first-line treatment of advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma. The combination therapy improved overall survival compared...

colorectal cancer

Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300

Dominik P. Modest, MD, of Charité-Universitätsmedizin Berlin, discusses phase III study findings showing sotorasib plus panitumumab vs trifluridine/tipiracil or regorafenib benefits patients with chemorefractory metastatic colorectal cancer in terms of improved clinical outcomes and better...

gastrointestinal cancer
immunotherapy

Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?

Yasunobu Ishizuka, MD, of Japan’s Aichi Cancer Center, discusses study results showing that scheduling infusions of nivolumab monotherapy before mid-afternoon for patients with metastatic gastric cancer may alter treatment efficacy. Several studies have suggested that circadian rhythm is essential...

hepatobiliary cancer

Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy

Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on tinengotinib, a next-generation FGFR inhibitor that seems to overcome acquired resistance and shows efficacy in patients with cholangiocarcinoma with other FGFR alterations who are not eligible...

gastrointestinal cancer
neuroendocrine tumors

Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin

Lorraine A. Chantrill, PhD, MBBS, of Australia’s Wollongong Hospital, New South Wales, discusses phase II findings on the combination of nab-paclitaxel plus carboplatin as a first-line treatment for patients with gastrointestinal neuroendocrine carcinomas. According to Dr. Chantrill, this regimen...

colorectal cancer
pancreatic cancer

Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab

Jennifer Yon-Li Wo, MD, of Massachusetts General Hospital, discusses the local failure rate of non-ablative hypofractionated radiation therapy in combination with the immune checkpoint inhibitors ipilimumab and nivolumab compared to ablative SBRT to treat metastatic microsatellite-stable colorectal ...

hepatobiliary cancer

Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab

Riccardo Lencioni, MD, of the University of Pisa School of Medicine, discusses phase III results from the EMERALD-1 study of durvalumab plus bevacizumab plus TACE (transarterial chemoembolization) in patients with embolization-eligible unresectable hepatocellular carcinoma. Compared with TACE...

colorectal cancer

Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker

Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II results on using circulating tumor DNA (ctDNA) as a predictive biomarker of adjuvant chemotherapy in patients with stage II colon cancer. During the trial, no improvement in ctDNA clearance was observed...

kidney cancer

Survival Benefit With Adjuvant Immunotherapy in Patients With Clear Cell RCC

The phase III KEYNOTE-564 study has reported that adjuvant pembrolizumab provides a significant improvement in overall survival for patients with clear cell renal cell carcinoma at high risk of recurrence after surgery. This study is significant, as it represents the first phase III study to show...

bladder cancer

AMBASSADOR: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma

Patients with muscle-invasive urothelial cancer and a high risk of recurrence after surgery may have a new treatment option. The Alliance for Clinical Trials in Oncology announced positive results from the phase III AMBASSADOR (A031501) trial for the adjuvant treatment of patients with localized...

gynecologic cancers
issues in oncology

Cervical Cancer Rates May Be Rising in Low-Income U.S. Counties

The incidence and mortality of cervical cancer may be rising in patients residing in low-income areas of the United States, according to a recent study published by Amboree et al in the International Journal of Cancer. Study Methods and Results In the recent study, investigators used the...

solid tumors
hematologic malignancies
issues in oncology

Secondary Cancers May Be Rare in Patients Treated With CAR T-Cell Therapy

The development of any type of secondary cancer following chimeric antigen receptor (CAR) T-cell therapy may be rare, according to a recent study published by Ghilardi et al in Nature Medicine. Background Secondary cancers, including T-cell lymphomas, are known risks of cancer treatments such as...

gastroesophageal cancer
gastrointestinal cancer

Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet

Anant Ramaswamy, DM, of Tata Memorial Centre, discusses phase III results of a study that added docetaxel to a doublet regimen of fluorouracil or capecitabine and oxaliplatin, which did not improve overall survival in patients with advanced gastroesophageal junction and gastric cancers. Continuing...

pancreatic cancer

Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel

Frank Kullmann, MD, of Germany’s Klinikum Weiden, discusses results from the ALPACA trial, which suggest a dose-reduced regimen with alternating cycles of gemcitabine/nab-paclitaxel and gemcitabine monotherapy after three induction cycles of standard gemcitabine/nab-paclitaxel is feasible and...

gastroesophageal cancer

Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy

Manish A. Shah, MD, of Weill Cornell Medical College, discusses phase III findings of the KEYNOTE-590 study, which shows that, after 5 years, the use of pembrolizumab plus chemotherapy improved survival with durable efficacy, compared with placebo plus chemotherapy, in patients with untreated...

prostate cancer

Cabozantinib and Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

Patients with metastatic castration-resistant prostate cancer with extrapelvic nodal or visceral metastasis who were treated with the combination of cabozantinib plus atezolizumab had significantly improved time to disease progression compared with those who were treated with hormonal therapy. This ...

supportive care
survivorship

Study Finds Plant-Rich Foods, Nuts/Seeds May Benefit Childhood Cancer Survivors

A recent study, published by Wang et al in the Journal of Clinical Oncology, conducted as part of the St. Jude Lifetime Cohort (SJLIFE), may provide new insights into how diet may affect aging in adult survivors of childhood cancer. This study, involving 3,322 participants aged 18 to 65, found that ...

solid tumors
hematologic malignancies
issues in oncology

Unintentional Weight Loss May Be a Warning Sign of Cancer, Study Finds

Unintentional weight loss may be associated with an increased risk of receiving a cancer diagnosis within the next year, according to a recent study published by Wang et al in JAMA. Background Patients with advanced cancer often experience weight loss. However, weight loss is often not thought to...

gastroesophageal cancer

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy

Ian Chau, MD, of The Royal Marsden Hospital, discusses an analysis from the CheckMate 648 study on quality-adjusted time without symptoms and toxicity in patients with unresectable advanced esophageal squamous cell carcinoma. Patients treated with nivolumab plus ipilimumab and nivolumab plus...

issues in oncology
immunotherapy

FDA Issues Safety Labeling Change Notification to CAR T-Cell Therapy Manufacturers

On January 19, the U.S. Food and Drug Administration (FDA) issued safety labeling change notification letters to all manufacturers of licensed B-cell maturation antigen (BCMA)-directed and CD19-directed genetically modified autologous chimeric antigen receptor (CAR) T-cell immunotherapies requiring ...

skin cancer
issues in oncology

Melanoma Overdiagnoses May Be Rising Among White U.S. Patients

Over 50% of all melanoma diagnoses among White patients in the United States may in fact be overdiagnoses, according to a recent study published by Adamson et al in BMJ Evidence-Based Medicine. Background “Cases of cutaneous melanoma have risen significantly in the [United States] over the last 40...

colorectal cancer
supportive care

Study Finds Majority of Patients With Lynch Syndrome Are Not Using Aspirin to Reduce Risk of Colon Cancer

Investigators have found that only a minority of patients with Lynch syndrome may be receiving aspirin as chemopreventive therapy, according to new findings presented by Singhal et al at the 2024 ASCO Gastrointestinal Cancers Symposium (Abstract 19). Background “[Patients] with Lynch syndrome are...

George D. Demetri, MD, FASCO, Earns Lifetime Achievement Award in Medicine From Stanford Medicine Alumni Association

George D. Demetri, MD, FASCO, Director of the Sarcoma Center at Dana-Farber Cancer Institute, was awarded the J.E. Wallace Sterling Lifetime Achievement Award in Medicine from the Stanford Medicine Alumni Association (SMAA). Dr. Demetri, an alumnus of the Stanford University School of Medicine,...

multiple myeloma

The High Cost of Oral Agents for Relapsed and Refractory Multiple Myeloma

Late in 2023, Richardson et al shared the results of a phase I/II clinical trial (ClinicalTrials.gov identifier NCT03374085). They concluded that the “all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma.”1 Mezigdomide ...

gastroesophageal cancer

Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648

Ken Kato, MD, PhD, of Japan’s National Cancer Center Hospital, discusses the first comprehensive findings on biomarkers from the CheckMate 648 study. These results further corroborate the clinical efficacy of nivolumab plus chemotherapy and nivolumab plus ipilimumab in the first-line treatment of...

gastroesophageal cancer

Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies

Michael K. Gibson, MD, PhD, of Vanderbilt University Medical Center, discusses phase III findings on chemotherapy plus camrelizumab in the ESCORT-NEO trial of patients with resectable esophageal squamous cell carcinoma; and phase III SKYSCRAPER-08 results on first-line tiragolumab plus atezolizumab ...

pancreatic cancer
issues in oncology

Novel Molecular Twin Tool May Improve Precision Medicine Care in Patients With Pancreatic Cancer

The novel artificial intelligence (AI)-based Molecular Twin Precision Oncology Platform may be capable of identifying biomarkers that may outperform the standard test for predicting pancreatic cancer survival, according to a recent study published by Osipov et al in Nature Cancer. Background...

prostate cancer
issues in oncology

Factors Influencing Selection of Active Surveillance for Low-Risk Prostate Cancer

Investigators may have uncovered some of the factors associated with the selection of active surveillance over surgery or radiation therapy in patients with low-risk prostate cancer, according to a recent study published by Xu et al in Cancer. Background Guidelines for low-risk prostate cancer that ...

neuroendocrine tumors

NETTER-2: Lu-177 Dotatate for Advanced Gastroenteropancreatic Neuroendocrine Tumors

Results from the first phase III clinical trial evaluating radioligand therapy in the first-line setting demonstrated that treatment with lutetium Lu-177 dotatate significantly improved progression-free survival and objective response rates in patients with high-grade gastroenteropancreatic...

hepatobiliary cancer

Adding Immunotherapy-Based Combination to TACE Improves Progression-Free Survival in HCC

The addition of durvalumab and bevacizumab to transarterial chemoembolization (TACE) significantly improved progression-free survival in patients with unresectable hepatocellular carcinoma who were eligible for embolization. According to the study authors, this is the first trial to demonstrate...

bladder cancer

FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma

On January 19, the U.S. Food and Drug Administration (FDA) approved the FGFR inhibitor erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations, as determined by an FDA-approved companion diagnostic test, whose...

hematologic malignancies
lymphoma
leukemia

Novel CAR NK-Cell Therapy May Offer Benefit in Patients With B-Cell Malignancies

A novel chimeric antigen receptor (CAR) natural killer (NK)-cell therapy may be effective at treating patients with relapsed or refractory B-cell malignancies, according to a novel study published by Marin et al in Nature Medicine. Study Methods and Results In the new phase I/II trial, researchers...

colorectal cancer

Do Patients With Molecular MRD Detected After Colorectal Cancer Surgery Benefit From Adjuvant Chemotherapy?

Following surgery to remove a colorectal tumor, patients may have molecular measurable residual disease (MRD). Circulating tumor DNA (ctDNA), or liquid biopsy, may be used to detect molecular MRD in patients who underwent surgery for colorectal cancer and to determine whether they may benefit from...

colorectal cancer

Role of Postoperative ctDNA in Patients With Low-Risk Stage IIA Colon Cancer

The role of circulating tumor DNA (ctDNA), or liquid biopsy, as a predictive tool to guide and monitor cancer treatment remains unclear, after the first prospective randomized phase II trial evaluating clearance of ctDNA in patients with stage II colon cancer receiving adjuvant chemotherapy did not ...

gastroesophageal cancer

Combining PD-L1 and TIGIT Inhibitors Plus Chemotherapy in Esophageal Cancer

Results from the phase III SKYSCRAPER-08 study found that combining PD-L1 and T-cell immunoglobulin and ITM domain (TIGIT) inhibitors plus chemotherapy in the first-line setting extended survival in an Asian population of patients with metastatic or locally advanced esophageal squamous cell...

colorectal cancer
issues in oncology

Combating Racial and Ethnic Disparities in Precision Medicine for Colorectal Cancer

Investigators may have uncovered molecular evidence of racial disparities in the receipt of precision medicine, according to a recent study published by Yamada et al in npj Precision Oncology. Background Colorectal cancer is the third most common cancer type diagnosed in both male and female...

lymphoma
issues in oncology

Investigators Highlight Characteristics Potentially Linked to Improved CAR T-Cell Therapy Outcomes in Large B-Cell Lymphoma

Investigators have assessed whether specific tumor characteristics were associated with improved outcomes in patients with large B-cell lymphoma who received chimeric antigen receptor (CAR) T-cell therapy, according to a recent study published by Locke et al in Nature Medicine. The findings may...

cns cancers
issues in oncology

Cannabis Use During Pregnancy May Be Linked to CNS Cancers in Children

Researchers may have identified an association between certain types of childhood cancers and cannabis use among pregnant patients, according to a recent study published by Wimberly et al in Cancer Epidemiology, Biomarkers & Prevention. The findings add specificity to the potential harms of...

lung cancer
immunotherapy

DXH9 Depletion May Expose Small Cell Lung Cancer Tumors to Immune System Attack

Researchers may have identified a novel genetic mechanism capable of making small cell lung cancer tumors more susceptible to an attack by the immune system, according to a new study published by Murayama et al in Cancer Discovery. The findings could lead to the development of new therapeutics to...

lung cancer
issues in oncology

Medicaid Expansion May Improve Postsurgical Survival Outcomes in Patients With NSCLC

Investigators have found that Medicaid expansion under the Affordable Care Act may be associated with a reduced risk of early mortality following surgical resection in patients with non–small cell lung cancer (NSCLC), according to a recent study published by Nogueira et al in JAMA Network Open. The ...

gynecologic cancers

FDA Approves Pembrolizumab Plus Chemoradiotherapy for FIGO 2014 Stage III–IVA Cervical Cancer

On January 12, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) with chemoradiotherapy for patients with International Federation of Gynecology and Obstetrics (FIGO) 2014 stage III–IVA cervical cancer. KEYNOTE-A18 Efficacy was evaluated in KEYNOTE-A18...

multiple myeloma
issues in oncology

Obesity and a Precursor of Multiple Myeloma

Patients with obesity may be more likely to have monoclonal gammopathy of undetermined significance, according to a recent study published by Lee et al in Blood Advances. Background Monoclonal gammopathy of undetermined significance—a benign hematologic condition characterized by an abnormal...

solid tumors
issues in oncology

Study Identifies Potential Variations in U.S. Health Insurance Coverage at Cancer Diagnosis by State

Investigators have uncovered substantial state variations in health insurance coverage among U.S. patients newly diagnosed with cancer, according to a recent study published by Hu et al in Health Affairs Scholar. Background Over the past decade, health insurance coverage—which has been found to be...

Advertisement

Advertisement




Advertisement